|Articles|September 1, 2002

Pharmaceutical Executive

  • Pharmaceutical Executive-09-01-2002

Dutch Government Just Says No

Author(s)Sarah Houlton

Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance.

Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance. It believes it should not have to pay for medi-cines for conditions brought on by unhealthy lifestyles, such as smoking and poor diet.

But plans to include cholesterol-reducing products on the list have worried the College voor Zorgverzekeringen (the Healthcare Insurance Board) which advises the government. The board has issued a report on statins, saying that their use should remain a part of basic health insurance because of their long-term preventive benefits.

Articles in this issue

about 24 years ago

More Statins = Fewer Heart Attacks

about 24 years ago

When Worlds Collide

about 24 years ago

Top European Trial Sponsors

about 24 years ago

Novo Nordisk Cancels Clinical Trials

about 24 years ago

Lilly Marketers Cross the Line

about 24 years ago

Spending Hits a Wall

about 24 years ago

Strangers in the Shadows

about 24 years ago

Plants and Patents

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.